Max Robotics — Global Service Robot Directory + US Certification

About

Oliver Kepp is a leading researcher in cancer biology and immunology, with a primary focus on immunogenic cell death (ICD), autophagy modulation, and high-throughput screening technologies. His major contributions include demonstrating that the oncolytic peptide LTX-315 triggers ICD by selectively permeabilizing mitochondrial membranes, leading to caspase-independent necrosis and robust T cell-mediated antitumor immunity—a finding with 129 citations that has opened new avenues for cancer immunotherapy. Kepp also showed that IGF1 receptor inhibition amplifies the effects of cancer drugs through autophagy-dependent and immune mechanisms, a study with 77 citations that highlights his work on pharmacological autophagy enhancement for age-associated diseases. Additionally, he co-developed methods for quantifying cellular viability using automated microscopy and flow cytometry (26 citations), providing essential tools for preclinical research. His high-throughput screening approaches for autophagy (3 citations) further underscore his technical expertise. Kepp’s work bridges fundamental cell death mechanisms with translational applications, making him a key figure in the development of novel anticancer strategies.